BidaskClub Lowers Endologix (ELGX) to Hold
BidaskClub cut shares of Endologix (NASDAQ:ELGX) from a buy rating to a hold rating in a research note issued to investors on Friday morning.
Other equities research analysts have also issued reports about the stock. Canaccord Genuity reiterated a hold rating and set a $5.00 target price on shares of Endologix in a research note on Monday, October 9th. Stifel Nicolaus set a $6.00 target price on shares of Endologix and gave the company a hold rating in a research note on Friday, October 6th. Royal Bank of Canada reiterated a hold rating and set a $5.00 target price on shares of Endologix in a research note on Tuesday, October 3rd. Piper Jaffray Companies reiterated an overweight rating on shares of Endologix in a research note on Tuesday, December 12th. Finally, ValuEngine lowered shares of Endologix from a sell rating to a strong sell rating in a research note on Friday, September 1st. One investment analyst has rated the stock with a sell rating, nine have assigned a hold rating and one has assigned a buy rating to the company’s stock. The stock has an average rating of Hold and a consensus target price of $5.41.
Shares of Endologix (ELGX) opened at $5.25 on Friday. The company has a debt-to-equity ratio of 2.61, a current ratio of 2.90 and a quick ratio of 2.11. Endologix has a 12 month low of $4.08 and a 12 month high of $7.66.
WARNING: “BidaskClub Lowers Endologix (ELGX) to Hold” was originally published by Watch List News and is the property of of Watch List News. If you are viewing this story on another domain, it was stolen and reposted in violation of US and international trademark & copyright legislation. The legal version of this story can be accessed at https://www.watchlistnews.com/bidaskclub-lowers-endologix-elgx-to-hold/1771090.html.
Endologix, Inc is engaged in developing, manufacturing, marketing and selling medical devices for the treatment of aortic disorders. The Company’s products are intended for the treatment of abdominal aortic aneurysms (AAA). The AAA products are built on one of two platforms, including traditional minimally invasive endovascular repair (EVAR) or endovascular sealing (EVAS), its solution for sealing the aneurysm sac while maintaining blood flow through two blood flow lumens.
Receive News & Ratings for Endologix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Endologix and related companies with MarketBeat.com's FREE daily email newsletter.